These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 32529802)

  • 21. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
    Stephan C; Lein M; Jung K; Schnorr D; Loening SA
    Cancer; 1997 Jan; 79(1):104-9. PubMed ID: 8988733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia.
    Kiebish MA; Tekumalla P; Ravipaty S; Dobi A; Srivastava S; Wu W; Patil S; Friss T; Klotz A; Srinivasan A; Cullen J; Rosner IL; Ali A; Laszlo S; Petrovic M; Fleshner N; Garren J; Miller G; Mahaveer Chand N; Rodrigues LO; Granger E; Kellogg MD; Luan S; Diamandis E; Akmaev VR; Sarangarajan R; Bountra C; Freedland SJ; McLeod DG; Narain NR
    Sci Rep; 2021 Jul; 11(1):15052. PubMed ID: 34302010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
    Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
    Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MMP26: A potential biomarker for prostate cancer.
    Cheng T; Li F; Wei R; Lv MQ; Zhou Y; Dai Y; Yuan Y; Jiang GY; Ma D; Gao QL
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):891-894. PubMed ID: 29270749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating Levels of Omentin, Leptin, VEGF, and HGF and Their Clinical Relevance with PSA Marker in Prostate Cancer.
    Fryczkowski M; Bułdak RJ; Hejmo T; Kukla M; Żwirska-Korczala K
    Dis Markers; 2018; 2018():3852401. PubMed ID: 30186533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Significance of Measuring Global Hydroxymethylation of White Blood Cell DNA in Prostate Cancer: Comparison to PSA in a Pilot Exploratory Study.
    Grelus A; Nica DV; Miklos I; Belengeanu V; Ioiart I; Popescu C
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29156615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of prostate-specific antigen RNA before and after radical retropubic prostatectomy and transurethral resection of the prostate using "Light-Cycler"-based quantitative real-time polymerase chain reaction.
    Straub B; Müller M; Krause H; Schrader M; Goessl C; Heicappell R; Miller K
    Urology; 2001 Nov; 58(5):815-20. PubMed ID: 11711374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.
    Li J; Dai L; Lei N; Xing M; Li P; Luo C; Casiano CA; Zhang JY
    Oncotarget; 2016 Jul; 7(28):43546-43556. PubMed ID: 27286458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia.
    Fu S; Zhang X; Niu Y; Wang RT
    Asian Pac J Cancer Prev; 2018 Mar; 19(3):699-702. PubMed ID: 29580043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Associations of
    Duy LV; Huong PT; Nam NT; Trang DT; Chau NTM; Thao TTP; Hoang NH; Tao NT; Mao CV; Xuan NT
    Front Biosci (Landmark Ed); 2024 Jul; 29(7):256. PubMed ID: 39082359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using Serological Proteome Analysis to Identify Serum Anti-Nucleophosmin 1 Autoantibody as a Potential Biomarker in European-American and African-American Patients With Prostate Cancer.
    Dai L; Li J; Xing M; Sanchez TW; Casiano CA; Zhang JY
    Prostate; 2016 Nov; 76(15):1375-86. PubMed ID: 27418398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of an ELISA for sPSP94 and utility of the sPSP94/sPSA ratio as a diagnostic indicator to differentiate between benign prostatic hyperplasia and prostate cancer.
    Mhatre DR; Mahale SD; Khatkhatay MI; Desai SS; Jagtap DD; Dhabalia JV; Tongaonkar HB; Desai MP; Dandekar SP; Varadkar AM
    Clin Chim Acta; 2014 Sep; 436():256-62. PubMed ID: 24952364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extracellular RNAs from Whole Urine to Distinguish Prostate Cancer from Benign Prostatic Hyperplasia.
    Stella M; Russo GI; Leonardi R; Carcò D; Gattuso G; Falzone L; Ferrara C; Caponnetto A; Battaglia R; Libra M; Barbagallo D; Di Pietro C; Pernagallo S; Barbagallo C; Ragusa M
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancer molecular detection in plasma samples by glutathione S-transferase P1 (GSTP1) methylation analysis.
    Dumache R; Puiu M; Motoc M; Vernic C; Dumitrascu V
    Clin Lab; 2014; 60(5):847-52. PubMed ID: 24839830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of Differential Patterns of Oxidative Biomarkers in Prostate Cancer Progression.
    Wu T; Kasper S; Wong RM; Bracken B
    Clin Genitourin Cancer; 2020 Apr; 18(2):e174-e179. PubMed ID: 31899150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A circulating miRNA assay as a first-line test for prostate cancer screening.
    Sharova E; Grassi A; Marcer A; Ruggero K; Pinto F; Bassi P; Zanovello P; Zattoni F; D'Agostino DM; Iafrate M; Ciminale V
    Br J Cancer; 2016 Jun; 114(12):1362-6. PubMed ID: 27228285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilot and feasibility study of serum chemokines as markers to distinguish prostatic disease in men with low total serum PSA.
    Macoska JA; Begley LA; Dunn RL; Siddiqui J; Wei JT; Sarma AV
    Prostate; 2008 Mar; 68(4):442-52. PubMed ID: 18196514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer.
    Khan S; Jutzy JM; Valenzuela MM; Turay D; Aspe JR; Ashok A; Mirshahidi S; Mercola D; Lilly MB; Wall NR
    PLoS One; 2012; 7(10):e46737. PubMed ID: 23091600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.